The European Patent Office (EPO) has published patent application EP4164672A2, filed by PharmaIN Corporation, detailing the use of C-type natriuretic peptides for cancer treatment. The application, published on March 11, 2026, includes specific peptide sequences and methods for their administration, classified under various International Patent Classifications related to pharmaceuticals and medical treatments.

This publication represents a new patent application and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and researchers in the oncology and peptide therapeutics space, indicating potential future intellectual property protection and market exclusivity for specific cancer treatments. Companies operating in this therapeutic area should monitor the patent's prosecution status and potential grant for competitive intelligence.